Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
3 Healthcare Stocks Positioned for Possible Market Outperformance
11:40am, Wednesday, 07'th Aug 2024
So far in 2024, healthcare stocks have run into periodic earnings challenges compared to historical first quarters. For example, quarterly earnings for healthcare stocks across the board were down 25%
Regeneron: Expanded Product Base Taking Root, More Is Certainly On The Way
11:15am, Wednesday, 07'th Aug 2024
Regeneron is a powerhouse in drug discovery with a promising pipeline and innovative treatments. Revenues are stable with flagship drugs like Eylea providing a revenue cushion and Dupixent driving gro
Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent
02:30pm, Monday, 05'th Aug 2024
Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.
Is Regeneron Pharmaceuticals Due for a Stock Split?
07:15am, Saturday, 03'rd Aug 2024
Regeneron shares have recently crossed over the $1,000 price point. The company has achieved significant growth and there could more to come.
Regeneron's Robust Pipeline And Financial Health Signal Continued Growth
07:39am, Friday, 02'nd Aug 2024
Regeneron's Q2 2024 revenue grew 12% year-over-year, reaching $3.55 billion. Dupixent's global net sales increased by 27% to $3.56 billion, driving overall revenue growth. Eylea HD mitigated market sh
Defensive Sectors Breakout: 3 Stocks to Buy Now for Protection
02:20pm, Thursday, 01'st Aug 2024
Over the past month we have observed some very interesting activity across the market's more defensive sectors, considerable outperformance. Below we can see just how significantly the Utilities ( XLU
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2024 Earnings Call Transcript
12:25pm, Thursday, 01'st Aug 2024
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations and Strategic Anal
Compared to Estimates, Regeneron (REGN) Q2 Earnings: A Look at Key Metrics
10:36am, Thursday, 01'st Aug 2024
The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
10:10am, Thursday, 01'st Aug 2024
Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.
Regeneron beats quarterly results on strong demand for eczema, eye treatments
08:42am, Thursday, 01'st Aug 2024
Drugmaker Regeneron Pharmaceuticals exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs.
Regeneron (REGN) Surpasses Q2 Earnings and Revenue Estimates
08:41am, Thursday, 01'st Aug 2024
Regeneron (REGN) came out with quarterly earnings of $11.56 per share, beating the Zacks Consensus Estimate of $10.57 per share. This compares to earnings of $10.24 per share a year ago.
Regeneron Stock Climbs After Strong Second-Quarter Performance
07:49am, Thursday, 01'st Aug 2024
A strong second-quarter performance lifted the already extended shares of the New York-based drugmaker Regeneron.
Regeneron Reports Second Quarter 2024 Financial and Operating Results
06:30am, Thursday, 01'st Aug 2024
TARRYTOWN, N.Y., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2024 and provided a business update.
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
02:35pm, Tuesday, 30'th Jul 2024
Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac
